EPHX2 and metabolic dysfunction-associated steatohepatitis: These findings suggest that 1,25 VD3 supplementation modulates AA metabolism in NASH, favoring anti-inflammatory pathways through increased EETs and decreased sEH activity, which may contribute to its protective effects against liver damage and inflammation in NASH.